Drug Pricing
Our work in Drug Pricing
-
Schaeffer Center Leads Innovation, Disparities Conversation at DC Event
The next Administration should prioritize increasing access to health care, especially for minorities and under-served communities.
Categorized in -
Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase
For high-cost specialty drug users, lack of an out-of-pocket cap in Part D has eaten savings from donut hole closure.
Categorized in -
In Los Angeles, PrEP and other HIV Prevention Strategies Found to be Cost-Effective
About 60,000 people live with HIV in LA County, and more than 1,800 become infected each year.
Categorized in -
Rethinking the Value of Survival: Clinical Trials Should Measure Patient Preferences for Survival versus Quality of Life upon Entry to Trials
Though clinical trials most often rely on average survival rates as measures of value, these are not synonymous indicators. Research by the Schaeffer Center finds additional factors may weigh in patient’s treatment choice.
Categorized in -
Specialty Drug Prices Offset Measures to Lower Medicare Patient Costs
Patients who struggle to pay for their drugs may not take their medicine as prescribed.
Categorized in -
Clinton and Trump are Both Wrong about Medicare’s Ability to Negotiate Drug Prices
The candidates should end their calls for Medicare to negotiate drug prices. It is a distraction and a non-starter for reducing the cost of medicines.
Categorized in -
Optimizing HCV Treatment: Moving beyond the Cost Conundrum
In this look at the use of new, highly effective but costly oral treatments for hepatitis C virus, the authors suggest that while many payers have instituted coverage policies that authorize treatment only for the sickest patients, patients should be treated before they progress too far toward end-stage disease.
Categorized in -
National Pharmaceutical Council and Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California Name New Health Policy Fellow
Ilene Hollin, PhD was selected for a two year fellowship in D.C.
-
Impact of Type 2 Diabetes Medication Cost Sharing on Patient Outcomes and Health Plan Costs
In this study of the association between cost sharing for type 2 diabetes medications, adherence, hospitalization rates, and healthcare costs, the researchers found that increased cost sharing was associated with reductions in pharmacy costs, but higher total costs for patients.
Categorized in